Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
GeriPal
DECEMBER 15, 2022
In an article in the NEJM (a published article this time, wonder of wonders!) And which of those experiences would you like to share with us that we could then write into a story that we’ll share with providers? But wait, there’s a shiny new anti-amyloid drug, lecanemab! (No This is Eric Widera. Alex: This is Alex Smith.
Let's personalize your content